"Designing Growth Strategies is in our DNA"

Vaccines Market Size, Share & COVID-19 Impact Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated, and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases (Hepatitis, Influenza, Human Papillomavirus, Measles/Mumps/Rubella, Rotavirus, Herpes Zoster, and Others), and Bacterial Diseases (Meningococcal Disease, Pneumococcal Disease, Diphtheria/Tetanus/Pertussis, and Others)), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers), and Region Forecast, 2021-2028

Region : Global | Format: PDF | Report ID: FBI101769

 

  1. Introduction
    1. Research Scope
    2. Market Segmentation
    3. Research Methodology
    4. Definitions and Assumptions
  2. Executive Summary
  3. Market Dynamics
    1. Market Drivers
    2. Market Restraints
    3. Market Opportunities
  4. Key Insights
    1. New Product Launches, key players
    2. Pipeline Analysis
    3. Technological Advancements in the Vaccines Market
    4. Prevalence of Disease Indications
    5. Key Industry Developments - Mergers, Acquisitions, and Partnerships
  5. Global Vaccines Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast – By Type
      1. Recombinant/Conjugate/Subunit
      2. Inactivated
      3. Live Attenuated
      4. Toxoid
    3. Market Analysis, Insights and Forecast – By Route of Administration
      1. Parenteral
      2. Oral
    4. Market Analysis, Insights and Forecast – By Disease Indication
      1. Viral Diseases
        1. Hepatitis
        2. Influenza
        3. Human Papillomavirus
        4. Measles/Mumps/Rubella
        5. Rotavirus
        6. Herpes Zoster
        7. Others
      2. Bacterial Diseases
        1. Meningococcal Disease
        2. Pneumococcal Disease
        3. Diphtheria/Tetanus/Pertussis
        4. Others
    5. Market Analysis, Insights and Forecast – By Age Group
      1. Pediatric
      2. Adults
    6. Market Analysis, Insights and Forecast – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Government Suppliers
      3. Others
    7. Market Analysis, Insights and Forecast – By Geography
      1. North America
      2. Europe
      3. Asia pacific
      4. Latin America
      5. Middle East & Africa
  6. North America Vaccines Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast  – By Type
      1. Recombinant/Conjugate/Subunit
      2. Inactivated
      3. Live Attenuated
      4. Toxoid
    3. Market Analysis, Insights and Forecast  – By Route of Administration
      1. Parenteral
      2. Oral
    4. Market Analysis, Insights and Forecast  – By Disease Indication
      1. Viral Diseases
        1. Hepatitis
        2. Influenza
        3. Human Papillomavirus
        4. Measles/Mumps/Rubella
        5. Rotavirus
        6. Herpes Zoster
        7. Others
      2. Bacterial Diseases
        1. Meningococcal Disease
        2. Pneumococcal Disease
        3. Diphtheria/Tetanus/Pertussis
        4. Others
    5. Market Analysis, Insights and Forecast  – By Age Group
      1. Pediatric
      2. Adults
    6. Market Analysis, Insights and Forecast  – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Government Suppliers
      3. Others
    7. Market Analysis, Insights and Forecast  – By Country
      1. U.S.
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      2. Canada
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
  7. Europe Vaccines Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast  – By Type
      1. Recombinant/Conjugate/Subunit
      2. Inactivated
      3. Live Attenuated
      4. Toxoid
    3. Market Analysis, Insights and Forecast  – By Route of Administration
      1. Parenteral
      2. Oral
    4. Market Analysis, Insights and Forecast  – By Disease Indication
      1. Viral Diseases
        1. Hepatitis
        2. Influenza
        3. Human Papillomavirus
        4. Measles/Mumps/Rubella
        5. Rotavirus
        6. Herpes Zoster
        7. Others
      2. Bacterial Diseases
        1. Meningococcal Disease
        2. Pneumococcal Disease
        3. Diphtheria/Tetanus/Pertussis
        4. Others
    5. Market Analysis, Insights and Forecast  – By Age Group
      1. Pediatric
      2. Adults
    6. Market Analysis, Insights and Forecast  – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Government Suppliers
      3. Others
    7. Market Analysis, Insights and Forecast  – By Country/Sub-region
      1. U.K.
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      2. Germany
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      3. France
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      4. Spain
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      5. Italy
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      6. Scandinavia
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      7. Rest of Europe
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
  8. Asia Pacific Vaccines Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast  – By Type
      1. Recombinant/Conjugate/Subunit
      2. Inactivated
      3. Live Attenuated
      4. Toxoid
    3. Market Analysis, Insights and Forecast  – By Route of Administration
      1. Parenteral
      2. Oral
    4. Market Analysis, Insights and Forecast  – By Disease Indication
      1. Viral Diseases
        1. Hepatitis
        2. Influenza
        3. Human Papillomavirus
        4. Measles/Mumps/Rubella
        5. Rotavirus
        6. Herpes Zoster
        7. Others
      2. Bacterial Diseases
        1. Meningococcal Disease
        2. Pneumococcal Disease
        3. Diphtheria/Tetanus/Pertussis
        4. Others
    5. Market Analysis, Insights and Forecast  – By Age Group
      1. Pediatric
      2. Adults
    6. Market Analysis, Insights and Forecast  – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Government Suppliers
      3. Others
    7. Market Analysis, Insights and Forecast  – By Country/Sub-region
      1. Japan
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      2. China
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      3. India
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      4. Australia
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      5. Southeast Asia
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      6. Rest of Asia Pacific
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
  9. Latin America Vaccines Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast  – By Type
      1. Recombinant/Conjugate/Subunit
      2. Inactivated
      3. Live Attenuated
      4. Toxoid
    3. Market Analysis, Insights and Forecast  – By Route of Administration
      1. Parenteral
      2. Oral
    4. Market Analysis, Insights and Forecast  – By Disease Indication
      1. Viral Diseases
        1. Hepatitis
        2. Influenza
        3. Human Papillomavirus
        4. Measles/Mumps/Rubella
        5. Rotavirus
        6. Herpes Zoster
        7. Others
      2. Bacterial Diseases
        1. Meningococcal Disease
        2. Pneumococcal Disease
        3. Diphtheria/Tetanus/Pertussis
        4. Others
    5. Market Analysis, Insights and Forecast  – By Age Group
      1. Pediatric
      2. Adults
    6. Market Analysis, Insights and Forecast  – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Government Suppliers
      3. Others
    7. Market Analysis, Insights and Forecast  – By Country/Sub-region
      1. Brazil
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      2. Mexico
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      3. Rest of Latin America
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
  10. Middle East & Africa Vaccines Market Analysis, Insights and Forecast, 2017-2028
    1. Key Findings / Summary
    2. Market Analysis, Insights and Forecast  – By Type
      1. Recombinant/Conjugate/Subunit
      2. Inactivated
      3. Live Attenuated
      4. Toxoid
    3. Market Analysis, Insights and Forecast  – By Route of Administration
      1. Parenteral
      2. Oral
    4. Market Analysis, Insights and Forecast  – By Disease Indication
      1. Viral Diseases
        1. Hepatitis
        2. Influenza
        3. Human Papillomavirus
        4. Measles/Mumps/Rubella
        5. Rotavirus
        6. Herpes Zoster
        7. Others
      2. Bacterial Diseases
        1. Meningococcal Disease
        2. Pneumococcal Disease
        3. Diphtheria/Tetanus/Pertussis
        4. Others
    5. Market Analysis, Insights and Forecast  – By Age Group
      1. Pediatric
      2. Adults
    6. Market Analysis, Insights and Forecast  – By Distribution Channel
      1. Hospital & Retail Pharmacies
      2. Government Suppliers
      3. Others
    7. Market Analysis, Insights and Forecast  – By Country/Sub-region
      1. GCC Countries
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      2. South Africa
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
      3. Rest of Middle East & Africa
        1. By Type
          1. Recombinant/Conjugate/Subunit
          2. Inactivated
          3. Live Attenuated
          4. Toxoid
  11. Competitive Analysis
    1. Key Industry Developments
    2. Global Market Share Analysis (2020)
    3. Competition Dashboard
    4. Comparative Analysis – Major Players
    5. Company Profiles (Overview, Products & Services, SWOT analysis, Recent Developments, Strategies, Financials (Based on Availability))
      1. GlaxoSmithKline plc.
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      2. Pfizer Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      3. Merck & Co., Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      4. Novartis AG
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      5. Emergent BioSolutions, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      6. CSL Limited
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      7. Inovio Pharmaceuticals, Inc.
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      8. Bavarian Nordic
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      9. Mitsubishi Tanabe Pharma Corporation.
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
      10. Other Prominent Players
        1. Overview,
        2. Products & Services,
        3. SWOT analysis,
        4. Recent Developments,
        5. Strategies,
        6. Financials (Based on Availability)
  12. Strategic Recommendations
Read Less

Figure 1:  Global Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2020 & 2028

Figure 2:  Global Vaccines Market Value Share (%), by Type, 2020 & 2028

Figure 3:  Global Vaccines Market Forecast (USD billion), by Recombinant/Conjugate/Subunit, 2017-2028

Figure 4:  Global Vaccines Market Forecast (USD billion), by Inactivated, 2017-2028

Figure 5:  Global Vaccines Market Forecast (USD billion), by Live Attenuated, 2017-2028

Figure 6:  Global Vaccines Market Forecast (USD billion), by Toxoid, 2017-2028

Figure 7:  Global Vaccines Market Value Share (%), by Route of Administration, 2020 & 2028

Figure 8:  Global Vaccines Market Forecast (USD billion), by Parenteral, 2017-2028

Figure 9:  Global Vaccines Market Forecast (USD billion), by Oral, 2017-2028

Figure 10:  Global Vaccines Market Value Share (%), by Disease Indication, 2020 & 2028

Figure 11:  Global Vaccines Market Forecast (USD billion), by Viral Diseases, 2017-2028

Figure 12:  Global Vaccines Market Forecast (USD billion), by Bacterial Diseases, 2017-2028

Figure 13:  Global Vaccines Market Value Share (%), by Age Group, 2020 & 2028

Figure 14:  Global Vaccines Market Forecast (USD billion), by Pediatric, 2017-2028

Figure 15:  Global Vaccines Market Forecast (USD billion), by Adults, 2017-2028

Figure 16:  Global Vaccines Market Value Share (%), by Distribution Channel, 2020 & 2028

Figure 17:  Global Vaccines Market Forecast (USD billion), by Hospital & Retail Pharmacies, 2017-2028

Figure 18:  Global Vaccines Market Forecast (USD billion), by Government Suppliers, 2017-2028

Figure 19:  Global Vaccines Market Forecast (USD billion), by Others, 2017-2028

Figure 20:  Global Vaccines Market Value (USD billion), by Region, 2020 & 2028

Figure 21:  North America Vaccines Market Value (USD billion), by Type, 2020 & 2028

Figure 22:  North America Vaccines Market Value Share (%), by Type, 2020

Figure 23:  North America Vaccines Market Value (USD billion), by Route of Administration, 2020 & 2028

Figure 24:  North America Vaccines Market Value Share (%), by Route of Administration, 2020

Figure 25:  North America Vaccines Market Value (USD billion), by Disease Indication, 2020 & 2028

Figure 26:  North America Vaccines Market Value Share (%), by Disease Indication, 2020

Figure 27:  North America Vaccines Market Value (USD billion), by Age Group, 2020 & 2028

Figure 28:  North America Vaccines Market Value Share (%), by Age Group, 2020

Figure 29:  North America Vaccines Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 30:  North America Vaccines Market Value Share (%), by Distribution Channel, 2020

Figure 31:  North America Vaccines Market Value (USD billion), By Country, 2020 & 2028

Figure 32:  North America Vaccines Market Value Share (%), By Country, 2020

Figure 33:  Europe Vaccines Market Value (USD billion), by Type, 2020 & 2028

Figure 34:  Europe Vaccines Market Value Share (%), by Type, 2020

Figure 35:  Europe Vaccines Market Value (USD billion), by Route of Administration, 2020 & 2028

Figure 36:  Europe Vaccines Market Value Share (%), by Route of Administration, 2020

Figure 37:  Europe Vaccines Market Value (USD billion), by Disease Indication, 2020 & 2028

Figure 38:  Europe Vaccines Market Value Share (%), by Disease Indication, 2020

Figure 39:  Europe Vaccines Market Value (USD billion), by Age Group, 2020 & 2028

Figure 40:  Europe Vaccines Market Value Share (%), by Age Group, 2020

Figure 41:  Europe Vaccines Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 42:  Europe Vaccines Market Value Share (%), by Distribution Channel, 2020

Figure 43:  Europe Vaccines Market Value (USD billion), By Country/ Sub-region, 2020 & 2028

Figure 44:  Europe Vaccines Market Value Share (%), By Country/ Sub-region, 2020

Figure 45:  Asia Pacific Vaccines Market Value (USD billion), by Type, 2020 & 2028

Figure 46:  Asia Pacific Vaccines Market Value Share (%), by Type, 2020

Figure 47:  Asia Pacific Vaccines Market Value (USD billion), by Route of Administration, 2020 & 2028

Figure 48:  Asia Pacific Vaccines Market Value Share (%), by Route of Administration, 2020

Figure 49:  Asia Pacific Vaccines Market Value (USD billion), by Disease Indication, 2020 & 2028

Figure 50:  Asia Pacific Vaccines Market Value Share (%), by Disease Indication, 2020

Figure 51:  Asia Pacific Vaccines Market Value (USD billion), by Age Group, 2020 & 2028

Figure 52:  Asia Pacific Vaccines Market Value Share (%), by Age Group, 2020

Figure 53:  Asia Pacific Vaccines Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 54:  Asia Pacific Vaccines Market Value Share (%), by Distribution Channel, 2020

Figure 55:  Asia Pacific Vaccines Market Value (USD billion), By Country/ Sub-region, 2020 & 2028

Figure 56:  Asia Pacific Vaccines Market Value Share (%), By Country/ Sub-region, 2020

Figure 57:  Latin America Vaccines Market Value (USD billion), by Type, 2020 & 2028

Figure 58:  Latin America Vaccines Market Value Share (%), by Type, 2020

Figure 59:  Latin America Vaccines Market Value (USD billion), by Route of Administration, 2020 & 2028

Figure 60:  Latin America Vaccines Market Value Share (%), by Route of Administration, 2020

Figure 61:  Latin America Vaccines Market Value (USD billion), by Disease Indication, 2020 & 2028

Figure 62:  Latin America Vaccines Market Value Share (%), by Disease Indication, 2020

Figure 63:  Latin America Vaccines Market Value (USD billion), by Age Group, 2020 & 2028

Figure 64:  Latin America Vaccines Market Value Share (%), by Age Group, 2020

Figure 65:  Latin America Vaccines Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 66:  Latin America Vaccines Market Value Share (%), by Distribution Channel, 2020

Figure 67:  Latin America Vaccines Market Value (USD billion), By Country/ Sub-region, 2020 & 2028

Figure 68:  Latin America Vaccines Market Value Share (%), By Country/ Sub-region, 2020

Figure 69:  Middle East & Africa Vaccines Market Value (USD billion), by Type, 2020 & 2028

Figure 70:  Middle East & Africa Vaccines Market Value Share (%), by Type, 2020

Figure 71:  Middle East & Africa Vaccines Market Value (USD billion), by Route of Administration, 2020 & 2028

Figure 72:  Middle East & Africa Vaccines Market Value Share (%), by Route of Administration, 2020

Figure 73:  Middle East & Africa Vaccines Market Value (USD billion), by Disease Indication, 2020 & 2028

Figure 74:  Middle East & Africa Vaccines Market Value Share (%), by Disease Indication, 2020

Figure 75:  Middle East & Africa Vaccines Market Value (USD billion), by Age Group, 2020 & 2028

Figure 76:  Middle East & Africa Vaccines Market Value Share (%), by Age Group, 2020

Figure 77:  Middle East & Africa Vaccines Market Value (USD billion), by Distribution Channel, 2020 & 2028

Figure 78:  Middle East & Africa Vaccines Market Value Share (%), by Distribution Channel, 2020

Figure 79:  Middle East & Africa Vaccines Market Value (USD billion), By Country/ Sub-region, 2020 & 2028

Figure 80:  Middle East & Africa Vaccines Market Value Share (%), By Country/ Sub-region, 2020

Figure 81:  Global Vaccines Market Share (%), By Company, 2020

Table 1:  Global Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 2:  Global Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2017-2028

Table 3:  Global Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2017-2028

Table 4:  Global Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2017-2028

Table 5:  Global Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2017-2028

Table 6:  Global Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2017-2028

Table 7:  Global Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 8:  Global Vaccines Market Revenue (USD billion) Forecast, by Region, 2017-2028

Table 10:  North America Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2017-2028

Table 11:  North America Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2017-2028

Table 12:  North America Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2017-2028

Table 13:  North America Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2017-2028

Table 14:  North America Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2017-2028

Table 15:  North America Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 16:  North America Vaccines Market Revenue (USD billion) Forecast, By Country, 2017-2028

Table 17:  U.S. Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 18:  Canada Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 19:  Europe Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 20:  Europe Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2017-2028

Table 21:  Europe Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2017-2028

Table 22:  Europe Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2017-2028

Table 23:  Europe Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2017-2028

Table 24:  Europe Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2017-2028

Table 25:  Europe Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 26:  Europe Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2028

Table 27:  Germany Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 28:  France Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 29:  U.K. Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 30:  Italy Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 31:  Spain Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 32:  Scandinavia Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 33: Rest of Europe Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 34:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 35:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2017-2028

Table 36:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2017-2028

Table 37:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2017-2028

Table 38:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2017-2028

Table 39:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2017-2028

Table 40:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 41:  Asia Pacific Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2028

Table 42:  India Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 43:  China Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 44:  Japan Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 45:  Australia Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 46:  South East Asia Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 47:  Rest of Asia Pacific Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 48:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 49:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2017-2028

Table 50:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2017-2028

Table 51:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2017-2028

Table 52:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2017-2028

Table 53:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2017-2028

Table 54:  Latin America Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 55:  Latin America Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2028

Table 56:  Brazil Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 57:  Mexico Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 58:  Rest of Latin America Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 59:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 60:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2017-2028

Table 61:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2017-2028

Table 62:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2017-2028

Table 63:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2017-2028

Table 64:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Age Group, 2017-2028

Table 65:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2017-2028

Table 66:  Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2017-2028

Table 67:  GCC Countries Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 68:  South Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Table 69: Rest of Middle East & Africa Vaccines Market Revenue (USD billion) Forecast, by Type, 2017-2028

Booklet
  • Feb, 2022
  • 2020
  • 2017-2019
  • 156

    CHOOSE LICENSE TYPE

  • $4850
    $5850
    $7850
    Compare Licenses Book Now

Healthcare Clients

3M
abbvie
Amgen
Ansell
Fresenius
Galemed
Grifols
Ipsos
iqvia
Johnson
Jubilant
Lek
Pfizer
Roche
Siemens Healthineers
Styker
uniliver

Related Reports

Client Testimonials

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X